Neuronetics, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

STIM$2.18+1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except per share data)



· · Years ended December 31,
· · 2024 · · 2023 · · 2022
Revenues	$74,890	$71,348	$65,206
Cost of revenues	20,729	19,643	15,483
Gross profit	54,161	51,705	49,723
Operating expenses:
Sales and marketing	45,631	47,318	49,982
General and administrative	30,322	25,426	25,516
Research and development	12,771	9,515	9,336
Total operating expenses	88,724	82,259	84,834
Loss from operations	(34,563)	(30,554)	(35,111)
Other (income) expense:
Interest expense	7,286	5,424	4,251
Loss on extinguishment of debt	4,427	—	—
Other income, net	(2,549)	(5,789)	(2,203)
Net loss	$(43,727)	$(30,189)	$(37,159)
Less: Non-controlling interest	19	—	—
Net loss attributable to Neuronetics stockholders’	$(43,708)	$(30,189)	$(37,159)
Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders’	$(1.38)	$(1.05)	$(1.38)
Weighted average common shares outstanding, basic and diluted	31,734	28,658	26,900

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.